Citations

Mayo Clinic

Showing 10 of 108585 citations.

Abstract 610: Using Bicarbonate Based Purge Solution As The Sole Anticoagulation Strategy In Impella 5.5-a Novel Approach
Halder, Anupam , Rajak, Kripa, Atrash, Anas , Goswami, Rohan

Arteriosclerosis, Thrombosis, and Vascular Biology | October 2, 2023 | Volume: 43 | Issue: Suppl_1 | Pages: No page available

10.1161/atvb.43.suppl_1.610 Get It

The Impella® (Abiomed; Danvers, MA) pumps are percutaneous, transvalvular mechanical circulatory support (MCS) devices that propel blood from left ventricle to aorta that are used to augment cardiac output in management of high-risk percutaneous coronary intervention (HRPCI), acute heart failure, or cardiogenic shock. These systems utilize a flow of purge fluid that runs countercurrent to the blood flow which prevents inline thrombosis and protein deposition. Guidelines generally recommend heparin-dextrose purge fluid, with BBPS reserved for patients with heparin intolerance or active bleeding. We present the first case of use of BBPS as an elective choice for purge fluid in a patient with severe cardiogenic shock.Patient is 56-year-old male with known history of hypertension, diabetes and hyperlipidemia who presented with acute onset shortness of breath secondary to acute heart failure in the setting of myocardial infarction. He underwent a HRPCI for a non revascularizable three vessel coronary artery disease. He was readmitted for cardiogenic shock complicated with ventricular tachycardia, fibrillation and high risk of sudden cardiac death, necessitating inpatient transplant evaluation. Left heart catheterization showed pulmonary artery pressure of 59/63, wedge of 29 and cardiac index of 2 on 0.125mcg/kg/hr of milrinone. He received aggressive diuresis, antiarrhythmics and inotropic support. With increasing milrinone requirement, Impella 5.5 was placed and his antiplatelet regimen was changed from oral prasugrel to intravenous cangrelor with aspirin. A clinical decision was made to use BBPS instead of heparin purge, based on institutional experience and clinical data. Purge pressure, flow, lactate dehydrogenase and hematocrit have remained stable about 1.5ml/hr, 500mm Hg, 230U/L and 30% respectively for 22 days post-impella placement as the patient awaits transplantation.Limited retrospective studies and animal data, have shown no change in purge pressure/flow with BBPS. However, most of the data remains limited to use in heparin-intolerant patients. Our experience has indicated the possibility to use BBPS without systemic anticoagulation with no short-term complication,however conclusive trial data needs to be generated.
Abstract 478: Aberrant Glycogen Synthase Kinase 3 Activation In Liver Sinusoidal Endothelial Cells Enhances Liver Inflammation In Nonalcoholic Steatohepatitis
Ibrahim, Samar H.

Arteriosclerosis, Thrombosis, and Vascular Biology | October 2, 2023 | Volume: 43 | Issue: Suppl_1 | Pages: No page available

10.1161/atvb.43.suppl_1.478 Get It

Nonalcoholic steatohepatis (NASH) is characterized by excess circulating toxic lipids, along with hepatic steatosis, and recruited myeloid cells-mediated liver inflammation. Myeloid cells adhesion to the liver sinusoidal endothelial cells (LSEC) and transendothelial migration are crucial elements in the inflammatory process, and LSEC under lipotoxic stress develop a pro-inflammatory phenotype known as endotheliopathy. However, the exact mechanisms of this phenomenon are obscure. To define the molecular mediators of LSEC endotheliopathy, we isolated primary mouse LSECs from C57BL/6J mice on chow or a NASH-inducing diet rich in fat, fructose, and cholesterol (FFC), and subjected them to multi-omics studies. An integrated pathway analysis of the mouse LSEC proteomics and transcriptomics indicates that leukocyte transendothelial migration and focal adhesion are the major pathways altered in NASH LSEC. To explore the LSEC intracellular signaling networks, we performed kinome profiling of the LSEC phospho-proteomics and identified Glycogen Synthase Kinase 3 (GSK3)β as the major hub, and the top kinase in NASH. We then confirmed that GSK3β is activated in primary human LSEC treated with the toxic lipid Palmitate (PA). PA also promoted the LSEC pro-inflammatory response by upregulating CXCL2 and intracellular adhesion molecule 1 (ICAM-1) , all of which were attenuated with the GSK3 inhibitor LY2090314 (LY). Using a collagen gel-based transmigration assay, we demonstrated that THP-1 monocyte migration through an LSEC monolayer treated with PA was reduced by LY. In FFC-fed mice, LY treatment ameliorated liver inflammation, injury, and fibrosis as assessed by reduced F4/80, MPO, and ICAM-1 immuno-staining, ALT serum levels and hepatic TUNEL-positive cells, Sirius red and alpha smooth muscle actin staining of the liver. Mice with NASH-induced diet had reduced haptic neutrophil and proinflammatory monocyte infiltration when treated with ICAM1 neutralizing antibody. Furthermore, we confirmed increased LSEC expression of ICAM1 in human with NASH. In conclusion, GSK3 inhibition attenuates toxic lipid induced LSEC pro-inflammatory phenotype and may serve as a potential therapeutic strategy in human NASH.
Abstract 460: Catalase Overexpression Modulates Plaque Fibrosis And Vascular Contractile Function In Aged Hyperlipidemic Mice
Rabib, Ali, Roos, Carolyn M, Hagler, Michael A , Zhang, Bin , Smith, Leslie A, Rababa’h, Abeer , Miller, Jordan D.

Arteriosclerosis, Thrombosis, and Vascular Biology | October 2, 2023 | Volume: 43 | Issue: Suppl_1 | Pages: No page available

10.1161/atvb.43.suppl_1.460 Get It

Background: Plaque fibrosis and re-differentiation of vascular smooth muscle cells (VSMCs) from a contractile to a “synthetic” phenotype are hallmarks of advanced atherosclerosis. While in vitro studies demonstrated a clear role of oxidative stress in the loss of VSMC contractile phenotypes, the roles of specific antioxidant mechanisms and their therapeutic utility remain unclear. Here we test the hypothesis that overexpression of catalase protects against excess plaque fibrosis and losses in contractile phenotypes in vivo . Methods: We used littermate-matched, hypercholesteremic (ldlr -/- /ApoB 100/100 ; LA) mice lacking a transgenic construct (LA-CAT 0/0 ) or harboring a single copy of the human catalase gene (LA-CAT Tg/0 ), which were fed a Western Diet for 3 or 12 months. Isolated organ bath chambers, histopathological analyses, and quantitative RT-PCR were used to assess vasomotor function, structure, and molecular changes in aorta. Results: Oxidative stress increased with disease progression in aortic tissue from LA-CAT 0/0 mice and was modestly reduced in LA-CAT Tg/0 mice. Collagen deposition and fiber thickness increased with disease progression in LA-CAT 0/0 mice, and these increases in fiber thickness were attenuated in LA-CAT Tg/0 mice at 12 months and more pronounced in male mice. In parallel, we observed favorable rightward shifts in the vascular stress-strain relationship in LA-CAT Tg/0 mice that were more pronounced in aged male mice. Interestingly, these structural changes were associated with improved contractile responses to either PGF 2α or serotonin in male LA-CAT Tg/0 mice at 12 months. Consistent with these changes, the contractile marker calponin-1 was profoundly reduced with increasing age in LA-CAT 0/0 mice, with these changes being partially attenuated in aging, male LA-CAT Tg/0 mice. In vitro, treatment of VSMCs with PEG-catalase attenuated BMP2-dependent contractile protein expression. Conclusion: These results demonstrate that moderate overexpression of catalase can attenuate deleterious fibrotic and contractile changes associated with prolonged progression of atherosclerosis. Future mechanistic investigation exploring the context-dependence of these changes (e.g., sex dependence) is warranted.
Abstract 335: Functional And Molecular Effects Of Catalase Haploinsufficiency In Early And Advanced Atherosclerosis
Hagler, Michael A , Roos, Carolyn M, Rababa’h, Abeer , Smith, Leslie , Miller, Jordan D.

Arteriosclerosis, Thrombosis, and Vascular Biology | October 2, 2023 | Volume: 43 | Issue: Suppl_1 | Pages: No page available

10.1161/atvb.43.suppl_1.335 Get It

Introduction: While increased hydrogen peroxide (H 2 O 2 ) accelerates atherosclerotic vascular disease, the role of catalase---which selectively metabolizes H 2 O 2 in lysosomes—is unclear. Given the established role of H 2 O 2 in accelerating osteogenic vascular calcification and vascular smooth muscle cell de-differentiation, we sought to determine the effects of reducing catalase in vivo on functional and molecular changes in aorta in early and late-stage atherosclerosis. Hypothesis: Haploinsufficiency of catalase will worsen vascular contractile function and promote ectopic osteogenesis in early and late-stage atherosclerosis. Methods: We used ldlr -/- /ApoB 100/100 (LA) mice, which were wild-type or heterozygous for catalase (LA-Cat +/+ or LA-Cat +/- , respectively) and fed a western diet for 3 or 12 months. Vasomotor function was assessed using an isolated organ chamber system. Gene expression of VSMC contractile proteins and osteogenic markers was quantified using qRT-PCR. Results: Endothelial function worsened over time in both strains of mice and was modestly worsened in LA-Cat +/- mice. Vascular contraction to PGF 2α was reduced with aging in LA-Cat +/+ mice, and unaffected by catalase deficiency at 3 months. Surprisingly, contractile tension in response to PGF 2α was increased in LA-Cat +/- at 12 months, with this effect being most pronounced in female mice. Consistent with previous literature, expression of VSMC contractile genes (smooth muscle α-actin and calponin-1) was decreased in all groups following 12 months of diet (p<0.0001), and expression of osteogenic genes (BMP2, Runx2, and osterix) increased with aging (p<0.05). Surprisingly, and in contrast to our contractile function data, these time-dependent changes in gene expression tended to be augmented in LA-Cat +/- mice compared to LA-Cat +/+ littermates. Conclusions: Our data suggest that systemic inactivation of one copy of catalase increases contractile function in aorta from aged, hypercholesterolemic mice while paradoxically increasing osteogenic signaling. Future investigation into the role of specific antioxidant enzymes in driving functional and structural changes in advanced vascular disease will be critical to informing therapeutic strategies in this domain.
Abstract 331: Clearance Of Senescent Cells Reduces Osteogenic And Fibrogenic Signaling In Fibrocalcific Aortic Valve Stenosis
Leon-Sanchez, Luisa F, Roos, Carolyn M, Hagler, Michael A , Huang, Runqing , Zhang, Bin , Posada, Eduardo, Kirkland, James L. , Tchkonia, Tamar , Miller, Jordan D.

Arteriosclerosis, Thrombosis, and Vascular Biology | October 2, 2023 | Volume: 43 | Issue: Suppl_1 | Pages: No page available

10.1161/atvb.43.suppl_1.331 Get It

Introduction: Senescent cell accumulation and senescence-associated secretory phenotype (SASP) are putative major mechanisms of tissue aging, and growing evidence suggests that pharmacological clearance of senescent cells slows progression of multiple age-related diseases. Here, we hypothesized that treating with a known senolytic, Fisetin (FIS), would reduce molecular drivers of fibrosis and calcification and ultimately slow disease progression of fibrocalcific aortic valve stenosis (FCAVS) in mice when initiated in mild/moderate stages of disease. Methods: Male and female Ldlr -/- / ApoB 100/100 mice were fed a western diet for 9 months and assigned to one of two treatment groups: FIS or vehicle, with treatment beginning at 6 months of diet. Results: Treatment with FIS reduced CDKN2A (p < 0.01) and SASP marker TNFα (p < 0.002) in both sexes, and consistent with our hypothesis was associated with reduced expression of the osteogenic markers RUNX2 (p < 0.021) and SPP1 (p < 0.006) in valve tissue from female mice. In contrast, expression of WNT5A was reduced in valves only from male mice (p < 0.004). In line with these molecular changes, valvular calcium burden (alizarin red staining) also tended to decrease in both sexes. Interestingly, TGFβ1 expression was significantly reduced (p < 0.018) in both sexes and was associated with reductions in collagen 3A1. These molecular changes in fibrogenic signaling manifested as a shift towards thinner collagen fibers only in male animals (p < 0.05). Functionally, slower progression of valvular dysfunction (declines in aortic valve cusp separation distance assessed with high-resolution echocardiography) was observed predominantly in females (p < 0.002). Conclusions: In conclusion, these data suggest that long-term, intermittent clearance of senescent cells robustly attenuates osteogenic and fibrogenic signaling in mild/moderate FCAVS, although the molecular, histopathological, and functional consequences of senolytic therapy may occur in a sex-specific manner. Future studies evaluating preclinical efficacy of senolytics should account for tissue and sex specificity and warrant longer-term treatment to assess the functional consequences of the biological and histopathological changes observed here.
Abstract 161: Ablation Of Intracellular Lipolytic Inhibitor G0S2 Promotes Vascular Lipolysis And Alleviates Diet-induced Atherosclerosis
Chen, Yongbin , Johnson, S. M. , Burr, Stephanie D. , Povero, Davide , McMahon, Cailin E., Johnson, Scott M, Liu, Jun

Arteriosclerosis, Thrombosis, and Vascular Biology | October 2, 2023 | Volume: 43 | Issue: Suppl_1 | Pages: No page available

10.1161/atvb.43.suppl_1.161 Get It

Adipose tissue plays a central role in the regulation of plasma triglyceride (TG) and fatty acid (FA) levels, whose elevation is associated with atherosclerotic cardiovascular disease (ASCVD). Circulating TGs are hydrolyzed by lipoprotein lipase (LPL), releasing FAs that are taken up by adipocytes. Conversely, lipolytic action of adipose tissue triglyceride lipase (ATGL) mobilizes intracellular TG storage, supplying FAs via circulation for utilization by other tissues. However, how intracellular lipolysis influences intravascular lipolysis and atherosclerotic development remains largely unknown. Herein, the current study aimed to explore the role of G0S2, a selective protein inhibitor of ATGL, in this particular context. When treated with a Western diet and antisense oligonucleotides (ASOs) targeting LDLR, mice with a global ablation of G0S2 exhibited a significantly reduced lesion formation in aorta and brachiocephalic artery than their wild type (WT) littermates. Despite of little to no impact on hypercholesterolemia, total plasma and lipoprotein-specific TG content were normalized in G0S2 -/- mice. While it did not elicit any effects on intestinal lipid adsorption and hepatic TG secretion, the G0S2 ablation resulted in considerable elevation of LPL activity and protein levels in both plasma and adipose tissue. Accordingly, these G0S2 -/- mice showed a greatly improved TG clearance upon an oral lipid challenge. Interestingly, transplantation of G0S2 -/- adipose tissue increased circulating LPL in the WD-treated WT mice, which subsequently displayed a profound reduction of plasma TG levels as well as alleviation of hepatic steatosis. By studying adipose tissue explants and primary adipocytes, we observed that the G0S2 ablation led to markedly improved insulin sensitivity, resulting in increased FOXO1 phosphorylation and decreased expression of the LPL inhibitor ANGPTL4. Together, our data indicate that in the absence of G0S2, upregulation of adipose tissue LPL plays an important role in the clearance of circulating TGs and alleviation of diet-induced hypertriglyceridemia and atherosclerosis. We thus conclude that adipocyte G0S2 acts as a critical switch of both intracellular and vascular lipolysis.
Abstract 145: CRISPRi-Perturb-seq In Endothelial Cells Links Atherosclerosis Risk Loci To Novel Klf2/4 Regulatory Genes
Gupta, Rajat M. , Schnitzler, Gavin R., Kang, Helen , Fang, Shi, Lee, Vivian S. , Zheng, Tony, Barry, Aurelie , Angom, Ramcharan Singh , Lee-Kim, Vivian, Ma, Rosa, Zhou, Ronghao , Mukhopadhyay, Debabrata , Engreitz, J

Arteriosclerosis, Thrombosis, and Vascular Biology | October 2, 2023 | Volume: 43 | Issue: Suppl_1 | Pages: No page available

10.1161/atvb.43.suppl_1.145 Get It

Introduction: Genome-wide association studies (GWAS) have discovered >300 associations for CAD. Few loci are functionally characterized and may represent new mechanisms of disease. Hypothesis: Can an unbiased transcriptional screen for the >2000 candidate GWAS genes in endothelial cells (ECs) identify causal genes and disease-relevant pathways at CAD GWAS loci. Methods: We applied CRISPRi-Perturb-seq to knock down expression of genes within 500 Kb of coronary artery disease GWAS loci (2,300 genes in total) and measure their transcriptomic effects using single-cell RNA-seq. Validation of candidate causal genes was conducted in primary human ECs and zebrafish. Results: We identified 50 programs of co-expressed genes, which represent core cellular pathways (i.e. ribosome biogenesis) and 13 EC-specific pathways such as flow response and angiogenesis. The EC-specific programs show the greatest contribution to CAD heritability. 5 EC-specific programs have the greatest number of GWAS candidate genes. We find that 43 of 306 CAD GWAS signals converge onto these 5 gene programs, and all are regulated by genes in the cerebral cavernous malformations (CCM) pathway—which coordinates KLF2/4 transcriptional responses in endothelial cells, but has not been linked to CAD risk. The strongest regulator of these programs is TLNRD1 , which we show is a new CAD gene and novel regulator of the CCM pathway. TLNRD1 loss-of-function alters actin organization and barrier function in endothelial cells in vitro , and heart development in zebrafish in vivo . Conclusions: High-throughput functional analysis of 2,300 genes proximal to CAD GWAS loci prioritized pathways—such as angiogenesis and EC migration—that are regulated by multiple risk SNPs. Our study identifies new genes that likely influence risk for CAD, identifies convergence of CAD genes into certain pathways in endothelial cells, and prioritizes study of genes in the CCM-signaling pathway for contribution to CAD risk.
Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy
Hálfdánarson, Þorvarður R. , Mallak, Nadine , Paulson, Scott, Natwa, Mona, Kendi, A. Tuba , Kennecke, Hagen F. , Kendi, A Tuba , Halfdanarson, Thorvardur R , Chandrasekharan, Chandrikha

Cancers | October 2, 2023 | Volume: 15 | Issue: 19 | Pages: 4836

10.3390/cancers15194836 | PMID 37835530 Get It

Radioligand therapy (RLT) with [177Lu]Lu-DOTA-TATE is a standard of care for adult patients with somatostatin-receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Taking advantage of this precision nuclear medicine approach requires diligent monitoring and surveillance, from the use of diagnostic SSTR-targeted radioligand imaging for the selection of patients through treatment and assessments of response. Published evidence-based guidelines assist the multidisciplinary healthcare team by providing acceptable approaches to care; however, the sheer heterogeneity of GEP-NETs can make these frameworks difficult to apply in individual clinical circumstances. There are also contradictions in the literature regarding the utility of novel approaches in monitoring and surveilling patients with GEP-NETs receiving RLT. This article discusses the emerging evidence on imaging, clinical biochemistry, and tumor assessment criteria in the management of patients receiving RLT for GEP-NETs; additionally, it documents our own best practices. This allows us to offer practical guidance on how to effectively implement monitoring and surveillance measures to aid patient-tailored clinical decision-making.
Machine Learning for Automated Classification of Abnormal Lung Sounds Obtained from Public Databases: A Systematic Review
García-Méndez, Juan , Lal, Amos , Tekin, Aysun , Pinevich, Yuliya , Lipatov, Kirill , Qamar, Shahraz , Ayala, Ivan N. , Khapov, Ivan, Gerberi, Dana , Diedrich, Daniel A. , Pickering, Brian W. , Herasevich, Vitaly , Garcia-Mendez, Juan P, Herasevich, Svetlana , Tekin, Aysun , Wang, Hsin-Yi, Ayala, Iván Nicolas , Gerberi, Danielle J , Diedrich, Daniel, Herasevich, Vitaly , Lal, Amos , Garcia-Mendez, Juan P., Lipatov, Kirill , Wang, Hsin‐Yi

Bioengineering | October 2, 2023 | Volume: 10 | Issue: 10 | Pages: 1155

10.3390/bioengineering10101155 | PMID 37892885 Get It

Pulmonary auscultation is essential for detecting abnormal lung sounds during physical assessments, but its reliability depends on the operator. Machine learning (ML) models offer an alternative by automatically classifying lung sounds. ML models require substantial data, and public databases aim to address this limitation. This systematic review compares characteristics, diagnostic accuracy, concerns, and data sources of existing models in the literature. Papers published from five major databases between 1990 and 2022 were assessed. Quality assessment was accomplished with a modified QUADAS-2 tool. The review encompassed 62 studies utilizing ML models and public-access databases for lung sound classification. Artificial neural networks (ANN) and support vector machines (SVM) were frequently employed in the ML classifiers. The accuracy ranged from 49.43% to 100% for discriminating abnormal sound types and 69.40% to 99.62% for disease class classification. Seventeen public databases were identified, with the ICBHI 2017 database being the most used (66%). The majority of studies exhibited a high risk of bias and concerns related to patient selection and reference standards. Summarizing, ML models can effectively classify abnormal lung sounds using publicly available data sources. Nevertheless, inconsistent reporting and methodologies pose limitations to advancing the field, and therefore, public databases should adhere to standardized recording and labeling procedures.
Significant Reduction in the Diagnosis of Barrett's Esophagus and Related Dysplasia During the COVID-19 Pandemic
Pokala, Sridevi K. , Williams, J. Lucas, Holub, Jennifer L., Calderwood, Audrey H. , Iyer, Prasad G. , Shaheen, Nicholas J. , Wani, Sachin , Dominitz, Jason A.

American Journal of Gastroenterology | October 2, 2023 | Volume: 119 | Issue: 2 | Pages: 251-261

10.14309/ajg.0000000000002527 | PMID 37782262 Get It

INTRODUCTION: The coronavirus disease 19 (COVID-19) pandemic disrupted endoscopy practices, creating unprecedented decreases in cancer screening and surveillance services. We aimed to assess the impact of the pandemic on the proportion of patients diagnosed with Barrett's esophagus (BE) and BE-related dysplasia and adherence to established quality indicators. METHODS: Data from all esophagogastroduodenoscopies in the GI Quality Improvement Consortium, a national repository of matched endoscopy and pathology data, were analyzed from January 2018 to December 2022. Four cohorts were created based on procedure date and COVID-19 data: pre-pandemic (January 2018 to February 2020), pandemic-phase I (March 2020 to July 2020), pandemic-phase II (August 2020 to May 2021), and pandemic-phase III (June 2021 to December 2022). Observed and expected number of BE and BE-related dysplasia cases per month and adherence to the Seattle biopsy protocol and recommended surveillance intervals for nondysplastic BE (NDBE) were evaluated. RESULTS: Among 2,446,857 esophagogastroduodenoscopies performed during the study period, 104,124 (4.3%) had pathology-confirmed BE. The histologic distribution was 87.4% NDBE, 1.8% low-grade dysplasia, 2.4% indefinite for dysplasia, and 1.4% high-grade dysplasia. The number of monthly BE (−47.9% pandemic-phase I, −21.5% pandemic-phase II, and −19.0% pandemic-phase III) and BE-related dysplasia (high-grade dysplasia: 41.2%, −27.7%, and −19.0%; low-grade dysplasia: 49.1%, −35.3%, and −26.5%; any dysplasia: 46.7%, −32.3%, and −27.9%) diagnoses were significantly reduced during the pandemic phases compared with pre-pandemic data. Adherence rates to the Seattle protocol and recommended surveillance intervals for NDBE did not decline during the pandemic. DISCUSSION: There was a significant decline in the number of BE and BE-related dysplasia diagnoses during the COVID-19 pandemic, with an approximately 50% reduction in the number of cases of dysplasia diagnosed in the early pandemic. The absence of a compensatory increase in diagnoses in the pandemic-phase II and III periods may result in deleterious downstream effects on esophageal adenocarcinoma morbidity and mortality.